Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer

NCT06746870 is registered in ClinicalTrials.gov with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. as lead sponsor.

NCT NCT06746870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06746870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer
Lead sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 31, 2024
Completion date
December 31, 2026
Enrollment
148 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc, tnbc